Prevalence and evolution of drug resistance HIV-1 variants in Henan, China.
To understand the prevalence and evolution of drug resistant HIV strains in Henan China after the implementation of free antiretroviral therapy for AIDS patients. 45 drug naïve AIDS patients, 118 AIDS patients who received three months antiretroviral therapy and 124 AIDS patients who received six months antiretroviral treatment were recruited in the southern part of Henan province. Information on general condition, antiretroviral medicines, adherence and clinical syndromes were collected by face to face interview. Meanwhile, 14 ml EDTA anticoagulant blood was drawn. CD4/CD8 T cell count, viral load and genotypic drug resistance were tested. The rates of clinical improvement were 55.1% and 50.8% respectively three months and six months after antiretroviral therapy. The mean CD4 cell count after antiretroviral therapy was significantly higher than in drug naïve patients. The prevalence rate of drug resistant HIV strains were 13.9%, 45.4% and 62.7% in drug naïve patients, three month treatment patients and six month treatment patients, respectively. The number of resistance mutation codons and the frequency of mutations increased significantly with continued antiretroviral therapy. The mutation sites were primarily at the 103, 106 and 215 codons in the three-month treatment group and they increased to 15 codon mutations in the six-month treatment group. From this result, the evolution of drug resistant strains was inferred to begin with the high level NNRTI resistant strain, and then develop low level resistant strains to NRTIs. The HIV strains with high level resistance to NVP and low level resistance to AZT and DDI were highly prevalent because of the AZT+DDI+NVP combination therapy. These HIV strains were also cross resistant to DLV, EFV, DDC and D4T. Poor adherence to therapy was believed to be the main reason for the emergence and prevalence of drug resistant HIV strains. The prevalence of drug resistant HIV strains was increased with the continuation of antiretroviral therapy in the southern part of Henan province. Measures, that could promote high level adherence, provide new drugs and change ART regimens in failing patients, should be implemented as soon as possible.
Li
Jing Yun
JY
AIDS Research Department, Institute of Microbiology and Epidemiology, Academy of Military Medical Science, Beijing 100071, China. lijy@nic.bmi.ac.cn
Li
Han Ping
HP
Li
Lin
L
Li
Hong
H
Wang
Zhe
Z
Yang
Kun
K
Bao
Zuo Yi
ZY
Zhuang
Dao Min
DM
Liu
Si Yang
SY
Liu
Yong Jian
YJ
Xing
Hui
H
Shao
Yi Ming
YM
D015496:CD4-Positive T-Lymphocytes; D002681:China / Q000453:epidemiology; D003430:Cross-Sectional Studies; D016049:Didanosine / Q000627:therapeutic use; D024921:Drug Resistance, Multiple, Viral / Q000235:genetics; D019143:Evolution, Molecular; D014644:Genetic Variation; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000821:virology*; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics*; D006801:Humans; D018655:Lymphocyte Count; D019829:Nevirapine / Q000627:therapeutic use; D015995:Prevalence; D015215:Zidovudine / Q000627:therapeutic use
D015215:Zidovudine; D019829:Nevirapine; D016049:Didanosine